Drug Watch

Latest News

FDA Approves Sofpironium (Sofdra) as First and Only Chemical Entity for Primary Axillary Hyperhidrosis
FDA Approves Sofpironium (Sofdra) as First and Only Chemical Entity for Primary Axillary Hyperhidrosis

June 21st 2024

Botanix Pharmaceuticals announced the approval of its sofpironium topical gel, 12.45% for adults and children ages 9 and older.

SFA-002 Shows Promise in Early Clinical Trial Psoriasis Cohorts
SFA-002 Shows Promise in Early Clinical Trial Psoriasis Cohorts

June 20th 2024

FDA Approves Tralokinumab Autoinjector for Adults With Moderate to Severe Atopic Dermatitis
FDA Approves Tralokinumab Autoinjector for Adults With Moderate to Severe Atopic Dermatitis

June 13th 2024

Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks
Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks

June 10th 2024

SDPA Poster Reports Positive Phase 3 Results of Dupilumab for PN
SDPA Poster Reports Positive Phase 3 Results of Dupilumab for PN

June 5th 2024

Video Interviews
Podcasts
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
The Cutaneous Connection

More News

© 2024 MJH Life Sciences

All rights reserved.